US Stock MarketDetailed Quotes
ABOS Acumen Pharmaceuticals
- 2.330
- -0.020-0.85%
Close Oct 15 16:00 ET
139.99MMarket Cap-2099P/E (TTM)
2.410High2.290Low102.15KVolume2.360Open2.350Pre Close239.23KTurnover0.32%Turnover RatioLossP/E (Static)60.08MShares5.09052wk High0.57P/B75.53MFloat Cap1.81052wk Low--Dividend TTM32.42MShs Float26.980Historical High--Div YieldTTM5.11%Amplitude1.810Historical Low2.342Avg Price1Lot Size
Acumen Pharmaceuticals Stock Forum
Sign in to post a comment
$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Acumen Pharmaceuticals (NASDAQ: ABOS) presented new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference 2024.
The research focuses on patient experiences, biomarker data, and a new ultra-sensitive assay for measuring s...
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Acumen Pharmaceuticals (NASDAQ: ABOS) presented new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference 2024.
The research focuses on patient experiences, biomarker data, and a new ultra-sensitive assay for measuring s...
4
1
$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC) 2024. The conference will be held in Philadelphia and online ...
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC) 2024. The conference will be held in Philadelphia and online ...
$Acumen Pharmaceuticals (ABOS.US)$
NEWS
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Sabirnetug demonstrated a favorable safety profile with low incidence of ARIA-E in early AD participants.
Target engagement with AβOs in cerebrospinal fluid increased in a dose-dependent manner, suggesting active removal of target from the brain.
Sabirnetug treatment led to changes in CSF and plasma bio...
NEWS
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Sabirnetug demonstrated a favorable safety profile with low incidence of ARIA-E in early AD participants.
Target engagement with AβOs in cerebrospinal fluid increased in a dose-dependent manner, suggesting active removal of target from the brain.
Sabirnetug treatment led to changes in CSF and plasma bio...
$Acumen Pharmaceuticals (ABOS.US)$ Acumen Pharmaceuticals Collaborates With Lonza Covering The Manufacture Of Sabirnetug (ACU193) For Alzheimer's Disease, For Clinical Development And Commercialization, If Approved
1
$Acumen Pharmaceuticals (ABOS.US)$
slowly moving up
slowly moving up
2
$Acumen Pharmaceuticals (ABOS.US)$ announced that it has entered into a senior secured loan and security agreement with K2 HealthVentures, a healthcare-focused specialty finance company.![]()
2
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Acumen Pharmaceuticals (ABOS.US)$ Just off ATL ( you know how i likes me some bottom bouncers, hehehe ) Earnings out Monday 11/13/23 BMO! But mainly for the following! Phase 1 data on ACU193/INTERCEPT-AD was very promising! The Recent collaboration & License agreement with HALOZYME Could make this Alzheimer’s treatment a game changer for patients by allowing the delivery of the drug Subcutaneously instead of IV? Which would be much more convenient and less inva...
1
$Acumen Pharmaceuticals (ABOS.US)$ Acumen Pharmaceuticals, Inc. And Halozyme Enter Global Collaboration And License Agreement To Develop Subcutaneous Formulation Of ACU193 With ENHANZE Technology![]()
$Acumen Pharmaceuticals (ABOS.US)$ $ACADIA Pharmaceuticals (ACAD.US)$ $Alliance Entertainment Holding (AENT.US)$ $Apellis Pharmaceuticals (APLS.US)$ $Baosheng Media Group (BAOS.US)$ $Femto Technologies (BCAN.US)$ $CEL-SCI (CVM.US)$ $Disney (DIS.US)$ $Equity Lifestyle Properties Inc (ELS.US)$ $FB Financial (FBK.US)$ $First Solar (FSLR.US)$ $GreenPower Motor (GP.US)$ $InterDigital (IDCC.US)$ $Knightscope (KSCP.US)$ $Nova Lifestyle (NVFY.US)$ $Salarius Pharmaceuticals (SLRX.US)$
1
1
$Nova Lifestyle (NVFY.US)$ $Femto Technologies (BCAN.US)$ $Alliance Entertainment Holding (AENT.US)$ $Disney (DIS.US)$ $Acumen Pharmaceuticals (ABOS.US)$ $Knightscope (KSCP.US)$ $Apellis Pharmaceuticals (APLS.US)$ $BridgeBio Pharma (BBIO.US)$ $Lixte Biotechnology (LIXT.US)$ $Harbor Custom Development (HCDI.US)$
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Lnova : Thank you for sharing